ID   NFKB1_RAT               Reviewed;         973 AA.
AC   Q63369; F1LQH2;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   28-JUN-2023, sequence version 2.
DT   24-JUL-2024, entry version 182.
DE   RecName: Full=Nuclear factor NF-kappa-B p105 subunit;
DE   AltName: Full=DNA-binding factor KBF1;
DE   AltName: Full=EBP-1;
DE   AltName: Full=Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1;
DE   Contains:
DE     RecName: Full=Nuclear factor NF-kappa-B p50 subunit;
GN   Name=Nfkb1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 452-973.
RC   STRAIN=Sprague-Dawley; TISSUE=Testis;
RX   PubMed=8161377; DOI=10.1210/endo.134.3.8161377;
RA   Hamil K.G., Hall S.H.;
RT   "Cloning of rat Sertoli cell follicle-stimulating hormone primary response
RT   complementary deoxyribonucleic acid: regulation of TSC-22 gene
RT   expression.";
RL   Endocrinology 134:1205-1212(1994).
RN   [3]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-757, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: NF-kappa-B is a pleiotropic transcription factor present in
CC       almost all cell types and is the endpoint of a series of signal
CC       transduction events that are initiated by a vast array of stimuli
CC       related to many biological processes such as inflammation, immunity,
CC       differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B
CC       is a homo- or heterodimeric complex formed by the Rel-like domain-
CC       containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and
CC       NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most
CC       abundant one. The dimers bind at kappa-B sites in the DNA of their
CC       target genes and the individual dimers have distinct preferences for
CC       different kappa-B sites that they can bind with distinguishable
CC       affinity and specificity. Different dimer combinations act as
CC       transcriptional activators or repressors, respectively. NF-kappa-B is
CC       controlled by various mechanisms of post-translational modification and
CC       subcellular compartmentalization as well as by interactions with other
CC       cofactors or corepressors. NF-kappa-B complexes are held in the
CC       cytoplasm in an inactive state complexed with members of the NF-kappa-B
CC       inhibitor (I-kappa-B) family. In a conventional activation pathway, I-
CC       kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to
CC       different activators, subsequently degraded thus liberating the active
CC       NF-kappa-B complex which translocates to the nucleus. NF-kappa-B
CC       heterodimeric p65-p50 and RelB-p50 complexes are transcriptional
CC       activators. The NF-kappa-B p50-p50 homodimer is a transcriptional
CC       repressor, but can act as a transcriptional activator when associated
CC       with BCL3. NFKB1 appears to have dual functions such as cytoplasmic
CC       retention of attached NF-kappa-B proteins by p105 and generation of p50
CC       by a cotranslational processing. The proteasome-mediated process
CC       ensures the production of both p50 and p105 and preserves their
CC       independent function, although processing of NFKB1/p105 also appears to
CC       occur post-translationally. p50 binds to the kappa-B consensus sequence
CC       5'-GGRNNYYCC-3', located in the enhancer region of genes involved in
CC       immune response and acute phase reactions. In a complex with MAP3K8,
CC       NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is
CC       released by proteasome-dependent degradation of NFKB1/p105.
CC       {ECO:0000250|UniProtKB:P19838}.
CC   -!- FUNCTION: [Nuclear factor NF-kappa-B p105 subunit]: P105 is the
CC       precursor of the active p50 subunit (Nuclear factor NF-kappa-B p50
CC       subunit) of the nuclear factor NF-kappa-B. Acts as a cytoplasmic
CC       retention of attached NF-kappa-B proteins by p105.
CC       {ECO:0000250|UniProtKB:P19838}.
CC   -!- FUNCTION: [Nuclear factor NF-kappa-B p50 subunit]: Constitutes the
CC       active form, which associates with RELA/p65 to form the NF-kappa-B p65-
CC       p50 complex to form a transcription factor. Together with RELA/p65,
CC       binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the
CC       enhancer region of genes involved in immune response and acute phase
CC       reactions. {ECO:0000250|UniProtKB:P19838}.
CC   -!- SUBUNIT: Component of the NF-kappa-B p65-p50 complex (By similarity).
CC       Homodimer; component of the NF-kappa-B p50-p50 complex (By similarity).
CC       Component of the NF-kappa-B p105-p50 complex (By similarity). Component
CC       of the NF-kappa-B p50-c-Rel complex (By similarity). Component of a
CC       complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3 (By
CC       similarity). Also interacts with MAP3K8 (By similarity). NF-kappa-B p50
CC       subunit interacts with NCOA3 coactivator, which may coactivate NF-
CC       kappa-B dependent expression via its histone acetyltransferase activity
CC       (By similarity). Interacts with TSC22D3; this interaction prevents
CC       nuclear translocation and DNA-binding (By similarity). Interacts with
CC       SPAG9 and UNC5CL (By similarity). NFKB1/p105 interacts with CFLAR; the
CC       interaction inhibits p105 processing into p50 (By similarity).
CC       NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2 (By
CC       similarity). Interacts with GSK3B; the interaction prevents processing
CC       of p105 to p50 (By similarity). NFKB1/p50 interacts with NFKBIE (By
CC       similarity). NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B
CC       p50 subunit interacts with NFKBID (By similarity). Directly interacts
CC       with MEN1 (By similarity). Interacts with HIF1AN (By similarity).
CC       Interacts with FEM1A; interaction is direct (By similarity).
CC       {ECO:0000250|UniProtKB:P19838, ECO:0000250|UniProtKB:P25799}.
CC   -!- INTERACTION:
CC       Q63369; P47196: Akt1; NbExp=9; IntAct=EBI-8498561, EBI-7204362;
CC       Q63369; Q99N34: Dffb; NbExp=2; IntAct=EBI-8498561, EBI-8498730;
CC   -!- SUBCELLULAR LOCATION: [Nuclear factor NF-kappa-B p105 subunit]:
CC       Cytoplasm {ECO:0000250|UniProtKB:P19838}.
CC   -!- SUBCELLULAR LOCATION: [Nuclear factor NF-kappa-B p50 subunit]: Nucleus
CC       {ECO:0000250|UniProtKB:P19838}. Cytoplasm
CC       {ECO:0000250|UniProtKB:P19838}. Note=Association with NFKBIA inhibitor
CC       (I-kappa-B), promotes its retention in the cytoplasm in an inactive
CC       form. Translocates into the nucleus following NFKBIA degradation.
CC       {ECO:0000250|UniProtKB:P19838}.
CC   -!- DOMAIN: The C-terminus of p105 might be involved in cytoplasmic
CC       retention, inhibition of DNA-binding, and transcription activation.
CC       {ECO:0000250|UniProtKB:P19838}.
CC   -!- DOMAIN: Glycine-rich region (GRR) is a critical element in the
CC       generation of p50 (Nuclear factor NF-kappa-B p50 subunit) by acting as
CC       a proteasomal 'stop signal', which leads to limited proteasomal
CC       degradation of the C-terminus, while generating p50.
CC       {ECO:0000250|UniProtKB:P19838}.
CC   -!- PTM: Generation of the NF-kappa-B p50 (Nuclear factor NF-kappa-B p50
CC       subunit) transcription factor takes place both cotranslationally and
CC       post-translationally via non-mutually exclusive mechanisms. A
CC       cotranslational processing allows the production of both p50 and p105
CC       (Nuclear factor NF-kappa-B p105 subunit) from a single NFKB1 mRNA.
CC       While translation occurs, the particular unfolded structure after the
CC       GRR repeat region acts as a substrate for the proteasome, promoting
CC       degradation of the C-terminus. The GRR acts as a proteasomal 'stop
CC       signal', protecting the region upstream of the GRR from degradation and
CC       promoting generation of p50. It is unclear if limited proteasome
CC       degradation during cotranslational processing depends on
CC       ubiquitination. NF-kappa-B p50 is also generated post-translationally
CC       following ubiquitination by the KPC complex, leading to limited
CC       processing by the proteasome downstream of the GRR region, thereby
CC       generating p50. {ECO:0000250|UniProtKB:P19838}.
CC   -!- PTM: [Nuclear factor NF-kappa-B p105 subunit]: Phosphorylation at the
CC       C-terminus by IKBKB/IKKB acts as a signal for ubiquitination and
CC       promotes either complete degradation or processing to generate the NF-
CC       kappa-B p50 (Nuclear factor NF-kappa-B p50 subunit) (By similarity).
CC       Phosphorylation at Ser-912 primes p105 for proteolytic processing in
CC       response to TNF-alpha stimulation (By similarity). Phosphorylation at
CC       Ser-928, Ser-932 and Ser-937 are required for BTRC/BTRCP-mediated
CC       ubiquitination and proteolysis (By similarity). Phosphorylation at Ser-
CC       932 is also required for ubiquitination by the KPC complex and limited
CC       processing to generate NF-kappa-B p50 (Nuclear factor NF-kappa-B p50
CC       subunit) (By similarity). {ECO:0000250|UniProtKB:P19838}.
CC   -!- PTM: [Nuclear factor NF-kappa-B p105 subunit]: Polyubiquitinated at
CC       multiple Lys residues in the C-terminus. Polyubiquitinated by the
CC       SCF(FBXW11) and SCF(BTRC) complexes following phosphorylation at Ser-
CC       928, Ser-932 and Ser-937, leading to its complete degradation. In
CC       contrast, polyubiquitination by the KPC complex following
CC       phosphorylation at Ser-932 leads to limited proteosomal processing and
CC       generation of the active NF-kappa-B p50 (Nuclear factor NF-kappa-B p50
CC       subunit). {ECO:0000250|UniProtKB:P19838}.
CC   -!- PTM: S-nitrosylation of Cys-60 affects DNA binding.
CC       {ECO:0000250|UniProtKB:P19838}.
CC   -!- PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-
CC       prostaglandin-J2 is autocatalytic and reversible. It may occur as an
CC       alternative to other cysteine modifications, such as S-nitrosylation
CC       and S-palmitoylation. {ECO:0000250|UniProtKB:P19838}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L26267; AAA20684.1; -; mRNA.
DR   PIR; I67414; I67414.
DR   RefSeq; XP_006233420.1; XM_006233358.3.
DR   AlphaFoldDB; Q63369; -.
DR   SMR; Q63369; -.
DR   CORUM; Q63369; -.
DR   IntAct; Q63369; 11.
DR   MINT; Q63369; -.
DR   STRING; 10116.ENSRNOP00000028944; -.
DR   iPTMnet; Q63369; -.
DR   PhosphoSitePlus; Q63369; -.
DR   PaxDb; 10116-ENSRNOP00000028944; -.
DR   PeptideAtlas; Q63369; -.
DR   AGR; RGD:70498; -.
DR   RGD; 70498; Nfkb1.
DR   VEuPathDB; HostDB:ENSRNOG00000023258; -.
DR   eggNOG; KOG0504; Eukaryota.
DR   HOGENOM; CLU_004343_1_0_1; -.
DR   InParanoid; Q63369; -.
DR   OrthoDB; 1059550at2759; -.
DR   TreeFam; TF325632; -.
DR   PRO; PR:Q63369; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000023258; Expressed in spleen and 19 other cell types or tissues.
DR   GO; GO:0000785; C:chromatin; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0035525; C:NF-kappaB p50/p65 complex; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0005667; C:transcription regulator complex; ISO:RGD.
DR   GO; GO:0042805; F:actinin binding; ISO:RGD.
DR   GO; GO:0003682; F:chromatin binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISO:RGD.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:RGD.
DR   GO; GO:0031072; F:heat shock protein binding; IPI:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:RGD.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:RGD.
DR   GO; GO:0003712; F:transcription coregulator activity; ISO:RGD.
DR   GO; GO:0140367; P:antibacterial innate immune response; ISO:RGD.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISO:RGD.
DR   GO; GO:0007249; P:canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:1904385; P:cellular response to angiotensin; ISO:RGD.
DR   GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IDA:RGD.
DR   GO; GO:0071322; P:cellular response to carbohydrate stimulus; IDA:RGD.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IDA:MGI.
DR   GO; GO:1904630; P:cellular response to diterpene; IDA:RGD.
DR   GO; GO:0071359; P:cellular response to dsRNA; ISO:RGD.
DR   GO; GO:1904632; P:cellular response to glucoside; IDA:RGD.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IDA:RGD.
DR   GO; GO:0097398; P:cellular response to interleukin-17; ISO:RGD.
DR   GO; GO:0071354; P:cellular response to interleukin-6; ISO:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:RGD.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; ISO:RGD.
DR   GO; GO:0071316; P:cellular response to nicotine; ISO:RGD.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:MGI.
DR   GO; GO:1901653; P:cellular response to peptide; IDA:RGD.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:RGD.
DR   GO; GO:0098586; P:cellular response to virus; ISO:RGD.
DR   GO; GO:0010467; P:gene expression; ISO:RGD.
DR   GO; GO:0007254; P:JNK cascade; ISO:RGD.
DR   GO; GO:0002523; P:leukocyte migration involved in inflammatory response; IEP:RGD.
DR   GO; GO:0060056; P:mammary gland involution; ISO:RGD.
DR   GO; GO:0000165; P:MAPK cascade; ISO:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0001818; P:negative regulation of cytokine production; ISO:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0038061; P:non-canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:RGD.
DR   GO; GO:1900127; P:positive regulation of hyaluronan biosynthetic process; ISO:RGD.
DR   GO; GO:2000630; P:positive regulation of miRNA metabolic process; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0060261; P:positive regulation of transcription initiation by RNA polymerase II; ISO:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0009617; P:response to bacterium; IEP:RGD.
DR   GO; GO:0046688; P:response to copper ion; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0035994; P:response to muscle stretch; ISO:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IDA:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IDA:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   CDD; cd08797; Death_NFkB1_p105; 1.
DR   CDD; cd01177; IPT_NFkappaB; 1.
DR   CDD; cd07935; RHD-n_NFkB1; 1.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR   Gene3D; 2.60.40.340; Rel homology domain (RHD), DNA-binding domain; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT_dom.
DR   InterPro; IPR033926; IPT_NFkappaB.
DR   InterPro; IPR047096; NF-kB_p105_DD.
DR   InterPro; IPR030503; NF-kB_p105_RHD_N.
DR   InterPro; IPR000451; NFkB/Dor.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd_sf.
DR   InterPro; IPR030492; RHD_CS.
DR   InterPro; IPR032397; RHD_dimer.
DR   InterPro; IPR011539; RHD_DNA_bind_dom.
DR   InterPro; IPR037059; RHD_DNA_bind_dom_sf.
DR   PANTHER; PTHR24169:SF9; NUCLEAR FACTOR NF-KAPPA-B P105 SUBUNIT; 1.
DR   PANTHER; PTHR24169; NUCLEAR FACTOR NF-KAPPA-B PROTEIN; 1.
DR   Pfam; PF00023; Ank; 2.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF16179; RHD_dimer; 1.
DR   Pfam; PF00554; RHD_DNA_bind; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   PRINTS; PR00057; NFKBTNSCPFCT.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00429; IPT; 1.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   SUPFAM; SSF81296; E set domains; 1.
DR   SUPFAM; SSF49417; p53-like transcription factors; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS01204; REL_1; 1.
DR   PROSITE; PS50254; REL_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; ANK repeat; Apoptosis; Cytoplasm; DNA-binding;
KW   Hydroxylation; Isopeptide bond; Lipoprotein; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; S-nitrosylation; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..973
FT                   /note="Nuclear factor NF-kappa-B p105 subunit"
FT                   /id="PRO_0000030314"
FT   CHAIN           1..483
FT                   /note="Nuclear factor NF-kappa-B p50 subunit"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT                   /id="PRO_0000030315"
FT   DOMAIN          38..245
FT                   /note="RHD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00265"
FT   REPEAT          540..570
FT                   /note="ANK 1"
FT   REPEAT          579..608
FT                   /note="ANK 2"
FT   REPEAT          612..641
FT                   /note="ANK 3"
FT   REPEAT          648..677
FT                   /note="ANK 4"
FT   REPEAT          682..711
FT                   /note="ANK 5"
FT   REPEAT          716..745
FT                   /note="ANK 6"
FT   REPEAT          769..799
FT                   /note="ANK 7"
FT   DOMAIN          803..890
FT                   /note="Death"
FT   REGION          371..394
FT                   /note="GRR"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   REGION          434..467
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          435..973
FT                   /note="Interaction with CFLAR"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   REGION          648..682
FT                   /note="Essential for interaction with HIF1AN"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOTIF           359..364
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        438..459
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            433..434
FT                   /note="Cleavage (when cotranslationally processed)"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         60
FT                   /note="S-nitrosocysteine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         336
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         440
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         449
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P25799"
FT   MOD_RES         676
FT                   /note="(3S)-3-hydroxyasparagine; by HIF1AN"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         757
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         898
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         912
FT                   /note="Phosphoserine; by GSK3-beta; in vitro"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         928
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         932
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         937
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         942
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   MOD_RES         948
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P25799"
FT   LIPID           60
FT                   /note="S-(15-deoxy-Delta12,14-prostaglandin J2-9-
FT                   yl)cysteine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
FT   CROSSLNK        324
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P19838"
SQ   SEQUENCE   973 AA;  105704 MW;  D88ECEA20A389AB7 CRC64;
     MADDDPFGTG QMFHLNTALT HSIFNAELYS TDIPLSTADG PYLQILEQPK QRGFRFRYVC
     EGPSHGGLPG ASSEKNKKSY PQVKICNYVG PAKVIVQLVT NGKNIHLHAH SLVGKHCEDG
     ICTVTAGPKD MVVGFANLGI LHVTKKKVFE TLEARMTEAC IRGYNPGLLV HSDLAYLQAE
     GGGDRQLTDR EKEIIRQAAL QQTKEMDLSV VRLMFTAFLP DSTGSFTRRL EPVVSDAIYD
     SKAPNASNLK IVRMDRTAGC VTGGEEIYLL CDKVQKDDIQ IRFYEEEENG GVWEGFGDFS
     PTDVHRQFAI VFKTPKYKDV NITKPASVFV QLRRKSDLET SEPKPFLYYP EIKDKEEVQR
     KRQKLMPNFS DSFGGGSGAG AGGGGMFGSG GGGGGSTGSP GPGYGFPHYG FPAYGGIAFH
     PGATKSNTGI THGTINTKFK NEPRDCAKSD DREILNPPEK ETQGEGPSLF MASTKTEAIA
     PASTMEDKEE DVGFQDNLFL EKALQLAKRH ANALFDYAVT GDVKMLLAVQ RHLTAVQDEN
     GDSVLHLAII HLHAQLVRDL LEVTSGSISD DIINMRNDLY QTPLHLAVIT KQEDVVEDLL
     RVGADLSLLD RWGNSVLHLA AKEGHDKILG VLLKNSKAAL LINHPNGEGL NAIHIAVMSN
     SLSCLQLLVA AGAEVNAQEQ KSGRTALHLA VEYDNISLAG CLLLEGDALV DSTTYDGTTP
     LHIAAGRGST RLAALLKAAG ADPLVENFEP LYDLDDSWEK AGEDEGVVPG TTPLDMAANW
     QVFDILNGKP YEPVFTSDDI LPQGDIKQLT EDTRLQLCKL LEIPDPDKNW ATLAQKLGLG
     ILNNAFRLSP APSKTLMDNY EVSGGTIKEL VEALRQMGYT EAIEVIQAAF RTPETTASSP
     VTTAQAHLLP LSSSSTRQHI DELRDNDSVC DSGVETSFRK LSFSESLTGD GPLLSLNKMP
     HNYGQDGPIE GKI
//
